The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.30

Today's change+0.01 +0.78%
Updated April 21 4:00 PM EDT. Delayed by at least 15 minutes.
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.30

Today's change+0.01 +0.78%
Updated April 21 4:00 PM EDT. Delayed by at least 15 minutes.

Arena Pharmaceuticals Inc up (U.S.)$0.01

Arena Pharmaceuticals Inc closed up Friday by (U.S.)$0.01 or 0.78% to (U.S.)$1.30. Over the last five days, shares have lost 9.09% and are down 8.45% for the last year to date. This security has underperformed the S&P 500 by 43.15% during the last year.

Key company metrics

  • Open(U.S.) $1.28
  • Previous close(U.S.) $1.29
  • High(U.S.) $1.32
  • Low(U.S.) $1.27
  • Bid / Ask(U.S.) $1.29 / (U.S.) $1.45
  • YTD % change-8.45%
  • Volume3,204,254
  • Average volume (10-day)3,986,305
  • Average volume (1-month)2,944,404
  • Average volume (3-month)2,024,198
  • 52-week range(U.S.) $1.20 to (U.S.) $2.16
  • Beta-1.01
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.09
Updated April 21 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-18.47%

Although this company's net profit margin is negative, it is above the industry average and implies that Arena Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.07%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue85191010
Total other revenue--------
Total revenue85191010
Gross profit791676
Total cost of revenue6334
Total operating expense47293629
Selling / general / administrative7997
Research & development12171919
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)2205--
Other operating expenses, total--------
Operating income38-10-26-19
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax38-12-27-22
Income after tax38-12-27-22
Income tax, total--------
Net income39-12-27-22
Total adjustments to net income--------
Net income before extra. items39-12-27-22
Minority interest00----
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items39-12-27-22
Inc. avail. to common incl. extra. items39-12-27-22
Diluted net income39-12-27-22
Dilution adjustment0000
Diluted weighted average shares243243243243
Diluted EPS excluding extraordinary itemsvalue per share0.16-0.05-0.11-0.09
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.25-0.05-0.09-0.09